Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | NNMT | P40261 | 2/20 | 0.44 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 4/20 | 0.33 |
| ▸ | CREBBP | Q92793 | 3/20 | 0.33 |
| ▸ | IDH1 | O75874 | 2/20 | 0.33 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | EP300 | Q09472 | 1/20 | 0.33 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8039039 | 0.81 | GSK3B (0.39) | GSK3BIDH1ADRA1A | |
| SCHEMBL12895008 | 0.81 | GSK3B (0.39) | TSHRGSK3BIDH1TNKS2ADRA1A | |
| SCHEMBL18068310 | 0.79 | GSK3B (0.37) | GSK3BIDH1ADRA1A | |
| SCHEMBL21281641 | 0.78 | GSK3B (0.36) | GSK3BIDH1TNKS2 | |
| SCHEMBL4183810 | 0.77 | GSK3B (0.34) | GSK3BIDH1TNKS2ADRA1A | |
| SCHEMBL28362032 | 0.77 | GSK3B (0.35) | GSK3BIDH1TNKS2ADRA1A | |
| SCHEMBL29550020 | 0.77 | GSK3B (0.35) | GSK3BIDH1TNKS2ADRA1A | |
| SCHEMBL21281656 | 0.76 | GSK3B (0.36) | GSK3BIDH1TNKS2 | |
| SCHEMBL20153297 | 0.76 | GSK3B (0.37) | GSK3BBRD4CREBBPIDH1ADRA1A | |
| SCHEMBL23583899 | 0.74 | DRD3 (0.38) | GSK3BIDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110818761-B | Preparation method of obeticholic acid intermediate | 东莞东阳光药物研发有限公司 | 2022-04-29 | — | — | CN | claimed |
| CN-110818761-A | Preparation method of obeticholic acid intermediate | 东莞东阳光药物研发有限公司 | 2020-02-21 | — | — | CN | claimed |
| WO-2025043225-A2 | DEGRADERS OF CYCLIN-DEPENDENT KINASE 2 | GENENTECH, INC. (US) | 2025-02-27 | — | — | WO | disclosed |
| WO-2024081363-A1 | COMPOSITION COMPRISING A FIRST RAS INHIBITOR, SECOND RAS INHIBITOR AND A SHP2 INHIBITOR FOR USE IN THE TREATMENT OF CANCER | Revolution Medicines, Inc. (US) | 2024-04-18 | — | — | WO | disclosed |
| US-11911381-B2 | Optically active azabicyclo ring derivative | Sumitomo Pharma Co., Ltd. (JP) | 2024-02-27 | — | — | US | disclosed |
| EP-4219479-A1 | PYRIMIDINE CARBOXAMIDE COMPOUND AND APPLICATION THEREOF | Shanghai Meiyue Biotech Development Co., Ltd. (CN) | 2023-08-02 | — | — | EP | disclosed |
| WO-2023104111-A1 | FUSED HETEROCYCLIC COMPOUNDS AS PI3KALPHA INHIBITORS | NANJING ZENSHINE PHARMACEUTICALS CO., LTD. (CN) | 2023-06-15 | — | — | WO | disclosed |
| US-11369605-B2 | Optically active azabicyclo ring derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2022-06-28 | — | — | US | disclosed |
| US-11325921-B2 | Optically active crosslinked cyclic secondary amine derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2022-05-10 | — | — | US | disclosed |
| CN-110818761-B | Preparation method of obeticholic acid intermediate | 东莞东阳光药物研发有限公司 | 2022-04-29 | — | — | CN | disclosed |
| WO-2022063197-A1 | PYRIMIDINE CARBOXAMIDE COMPOUND AND APPLICATION THEREOF | 上海美悦生物科技发展有限公司 | 2022-03-31 | — | — | WO | disclosed |
| EP-1939187-A1 | Substituted heteroaryl pyridopyrimidone derivatives | Sanofi-Aventis (FR) | 2008-07-02 | — | — | EP | disclosed |
| US-7348333-B2 | Cycloalkyl derivatives as inhibitors of bone resorption and vitronectin receptor antagonists | AVENTIS PHARMA S.A. (FR) | 2008-03-25 | — | — | US | disclosed |
| US-20080058348-A1 | Bone disorders such as osteoporosis, tumors and cardiovascular disorders; 4-(2-carboxy-2-Boc-aminoethylamino)-6-piperidinopyrimidines such as tert-butyl 2-benzyloxycarbonylamino-3-[2,5-dimethoxy-6-(4-[1,8]naphthyridin-2-yl-piperidin-1-yl)pyrimidin-4-ylamino]-propionate | PROSKELIA SAS | 2008-03-06 | — | — | US | disclosed |
| US-20080021055-A1 | Novel cycloalkyl derivatives as inhibitors of bone resorption and vitronectin receptor antagonists | AVENTIS PHARMA S.A. | 2008-01-24 | — | — | US | disclosed |
| US-20070203209-A1 | Useful indole compounds | IRONWOOD PHARMACEUTICALS, INC. | 2007-08-30 | — | — | US | disclosed |
| US-20070066607-A1 | Quinoline-2-one derivatives for the treatment of airways diseases | NOVARTIS AG (CH) | 2007-03-22 | — | — | US | disclosed |
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | JAPAN TOBACCO INC. (JP) | 2007-02-08 | — | — | US | disclosed |
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | JAPAN TOBACCO INC. (JP) | 2007-02-08 | — | — | US | disclosed |
| WO-2006004880-A2 | SUBSTITUTED N-ARYLSULFONYLHETEROCYCLIC AMINES AS GAMMA-SECRETASE INHIBITORS | SCHERING CORPORATION (US) | 2006-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11369605-B2 | Optically active azabicyclo ring derivative | MLLT3, MEN1, MLLT1 | TSHR 3676/4885NNMT 3397/4885GSK3B 4144/4885 |
| US-11911381-B2 | Optically active azabicyclo ring derivative | MLLT3, MEN1, MLLT1 | TSHR 3525/4885NNMT 3485/4885GSK3B 4371/4885 |
| US-20080021055-A1 | Novel cycloalkyl derivatives as inhibitors of bone resorption and vitronectin receptor antagonists | ADGRF1, ADGRE5, CALCR | TSHR 733/4885NNMT 4551/4885GSK3B 3604/4885 |
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | PYGL, GYS2, AGL | TSHR 1758/4885NNMT 2977/4885GSK3B 75/4885 |
| US-11325921-B2 | Optically active crosslinked cyclic secondary amine derivative | MLLT3, MEN1, MLLT1 | TSHR 3773/4885NNMT 4045/4885GSK3B 3676/4885 |
| US-20080058348-A1 | Bone disorders such as osteoporosis, tumors and cardiovascular disorders; 4-(2-carboxy-2-Boc-aminoethylamino)-6-piperidinopyrimidines such as tert-butyl 2-benzyloxycarbonylamino-3-[2,5-dimethoxy-6-(4-[1,8]naphthyridin-2-yl-piperidin-1-yl)pyrimidin-4-ylamino]-propionate | CALCR, PTH1R, CALCRL | TSHR 210/4885NNMT 2722/4885GSK3B 2468/4885 |
| US-20070066607-A1 | Quinoline-2-one derivatives for the treatment of airways diseases | ADRB2, ADRA2C, ADRB1 | TSHR 746/4885NNMT 2283/4885GSK3B 2764/4885 |
| US-20070203209-A1 | Useful indole compounds | TPH2, HRH2, HRH1 | TSHR 2205/4885NNMT 748/4885GSK3B 1453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.